ArticleSchizophrenia research2026
Aripiprazole two-month long-acting injectable may increase time to readmission compared to aripiprazole one-month in patients with schizophrenia and schizoaffective disorder.
Article in Schizophrenia research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveSchizophrenia and schizoaffective disorder are primarily treated with antipsychotic medications, including long-acting injectables (LAIs) which help reduce relapse/readmission. New LAIs have longer duration of action, including aripiprazole which now is available in bimonthly and monthly formulations. This study aimed to examine if bimonthly aripiprazole LAI (ARI-2) led to reduced readmissions and longer time to readmission compared to monthly aripiprazole LAI (ARI-1).
methodsThis retrospective cohort study examined all patients psychiatrically hospitalized in a metropolitan health system who had the diagnosis of schizophrenia or schizoaffective disorder, and who received aripiprazole LAI between January 1, 2020 and October 13, 2022 (N = 160). Baseline sociodemographic and clinical data were collected, as well as information on readmission. Differences between ARI-1 and ARI-2 groups were examined across a 1-year period.
resultsARI-1 and ARI-2 groups were largely similar in terms of baseline characteristics, with ARI-2 having more undomiciled patients and ARI-1 a greater number of prior hospitalizations. Readmission rates between the groups were similar. ARI-2 had significantly longer time to rehospitalization compared to ARI-1, by over 60 days on average. When controlling for confounding variables, such as prior hospitalizations, being undomiciled, and length of stay, only receiving ARI-2 was found to independently predict longer time to rehospitalization among those rehospitalized within 1 year.
conclusionThis real-world study found that receiving bimonthly aripiprazole LAI may be associated with improved outcomes over the course of one year compared to monthly, specifically in delaying time to rehospitalization. Our results are consistent with prior literature. Further research is needed to directly compare ARI-1 and ARI-2 over longer periods of time.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.